Important Safety Information | Prescribing Information



                            ADDITIONAL RESOURCES



Bausch + Lomb is committed to providing resources that can help you incorporate PROLENSA
into your practice, and we strive to develop tools that ensure continual product education.


 

Peer to Peer Videos


In this video series, we invite you to sit down with influential ophthalmologists and key members of their surgical staff as they discuss why PROLENSA is their post-cataract surgery NSAID of choice and how they’ve implemented successful treatment protocols in their practices to ensure patients receive PROLENSA as prescribed.


Choosing PROLENSA


Establishing a Treatment
Protocol for Your Practice

Communicating Treatment Protocol
With Patients

Executing Treatment Protocol Within
Your Practice



 

Educational Videos

Clinical experience
with PROLENSA


Discussing the importance of branded
products with your patients


Pharmacy switch conversation
with your patients


Co-pay assistance for PROLENSA


Why I use PROLENSA


The experts in bromfenac


Innovation of the Bromfenac Molecule


Commitment to Patient Access


Experts in the Evolution of Bromfenac




 

Published Articles

Read articles published by your colleagues about their clinical experience with PROLENSA.

Combining strategies in the counseling
and care of patients with cataracts


Spending more time talking to
pharmacists than talking to patients?




 

Professional Resources

                                                               

Tools for your patients’ post-operative experience.

Create customized medication regimen
instruction sheets for your patients


Purchase kits (cataract & refractive) to help
with your patients' post-operative care




Learn why PROLENSA is right for your patients ››    




INDICATION AND USAGE

PROLENSA (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

IMPORTANT SAFETY INFORMATION ABOUT PROLENSA

  • PROLENSA contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

  • All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

  • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs.

  • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

  • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

  • PROLENSA should not be instilled while wearing contact lenses. The preservative in PROLENSA, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA.

  • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.

Please click here for Prescribing Information about PROLENSA.
Please click here for references.

PRA.0042.USA.18